PDT联合ranibizumab玻璃体腔注射治疗年龄相关性黄斑变性合并CNV
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

基金项目:

2014年广东省建设中医药强省立项资助科研课题(No.20141272)


PDT combined with intravitreal injection of ranibizumab treatment for age-related macular degeneration with CNV
Author:
Affiliation:

Fund Project:

Construction of Strong TCM Province Research Project in 2014 of Guangdong Province(No. 20141272)

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察PDT联合玻璃体腔注射ranibizumab(雷珠单抗)治疗老年性黄斑变性脉络膜新生血管(choroidal neovascularization,CNV)的疗效。

    方法:将符合纳入标准,经吲哚青绿脉络膜血管造影(indocyanine green angiography, ICGA)、光学相干断层扫描(optical coherence tomography, OCT)检查确诊为黄斑区脉络膜新生血管(CNV)患者27例27眼,经PDT治疗后3~7d内行ranibizumab玻璃体腔注射。观察治疗后1,3,6mo、末次随访时行最佳矫正视力、FFA、ICGA、OCT检查及有无并发症发生情况。

    结果:最佳矫正视力提高17眼(63%),最佳矫正视力稳定6眼(22%),最佳矫正视力下降4眼(15%)。27例27眼治疗前平均渗漏面积为1 005.69±105.47μm,治疗后1,3mo后平均875.54±103.27,423.37±79.68μm,与治疗前比较差异有统计学意义(P<0.01), 视网膜黄斑中央厚度27例27眼治疗前平均厚度为485.58±122.59μm,治疗后1,3mo后平均398.84±105.32,297.74±89.18μm,与治疗前比较差异有统计学意义(P<0.01)。

    结论:PDT封闭CNV后,联合玻璃体内腔内注射ranibizumab,有效阻断新生血管复发,减少PDT再次治疗次数和并发症,可提高治疗效果。

    Abstract:

    AIM: To observe the curative effect of PDT combined with intravitreal injection of ranibizumab treatment for age-related macular degeneration with choroidal neovascularization(CNV).

    METHODS: In accordance with the inclusion criteria, by indocyanine green choroidalangiography(ICGA)and optical coherence tomography(OCT)examination confirmed the diagnosis of macular CNV in 27 patients(27 eyes), treated with PDT 3~7d professional intravitreal injection of ranibizumab. At 1, 3, 6mo after treatment, the results of best corrected visual acuity(BCVA), FFA, ICGA, OCT examination and complications were observed.

    RESULTS: The BCVA improved in 17 eyes(63%), stable in 6 eyes(22%), and decreased in 4 eyes(15%). Before treatment, the average leakage area was 1 005.69±105.47μm, it were 875.54±103.27μm, and 423.37±79.68μm at 1 and 3mo after treatment, there were significant differences compared with before treatment(P<0.01). Average central macular thickness of retina before treatment was 485.58±122.59μm, and 398.84±105.32μm, 297.74±89.18μ m at 1 and 3mo after treatment, there were significant differences compared with before treatment(P<0.01).

    CONCLUSION: The method that PDT closed CNV combined with intravitreal injection of ranibizumab can effectively block angiogenesis recurrence, reduce the number of PDT treatment again and complications, improve the therapeutic effect.

    参考文献
    相似文献
    引证文献
引用本文

杨雪艳,何锦贤,梁先军,等. PDT联合ranibizumab玻璃体腔注射治疗年龄相关性黄斑变性合并CNV.国际眼科杂志, 2015,15(4):659-661.

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2014-11-19
  • 最后修改日期:2015-03-25
  • 录用日期:
  • 在线发布日期: 2015-04-08
  • 出版日期:
文章二维码